Current filters:


Popular Filters

1890 to 1914 of 2375 results

Pharma industry calls for broad-based cooperation to fight on-line sales of counterfeit medicines


The global pharmaceutical industry unveiled recommendations this week to tackle the growing public health…

BiotechnologyGenericsGlobalMarkets & MarketingPharmaceuticalRegulation

US govt plans innovative public-private partnerships to turn the tide in fight against HIV/AIDS


In a speech at the opening session of the XIX International AIDS Conference (AIDS 2012) in Washington…

Anti-viralsBiotechnologyHealthcareNorth AmericaPharmaceutical

Onyx soars as FDA approves Kyprolis for multiple myeloma


Shares of US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) leapt 11.7% to $76.38 on Friday, after…

BiotechnologyKyprolisNorth AmericaOncologyOnyx PharmaceuticalsRegulation

Synergy Pharma and Callisto enter merger accord


USA-based biopharma groups Synergy Pharmaceuticals (Nasdaq: SGYP) and Callisto Pharmaceuticals (OTCBB:…

BiotechnologyCallisto PharmaceuticalsMergers & AcquisitionsSynergy Pharmaceuticals

Barriers to overcome in lupus drug development


It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

Actelion hikes earnings outlook despite lower sales


Switzerland-based Actelion (ATLN: VX), Europe's largest biotech company, reported first-half 2012 financial…


Pharmaceutical supply chain in Japan sees squeezed margins


Pressures felt in Japan as a result of the country's aging population, drug price revisions and patent…

Asia-PacificBiotechnologyFinancialMarkets & MarketingMergers & AcquisitionsPharmaceuticalPricing

SYGNIS and GENETRIX to combine subsidiary X-Pol business


German biotech firms SYGNIS Pharma AG (Frankfurt: LIOK) and GENETRIX have signed a binding term sheet…

BiotechnologyGENETRIXMergers & AcquisitionsQualiphiSYGNIS Pharma

EU Commission proposes to revamp rules on clinical trials to make Europe more attractive for research


With the aim of boosting clinical research in Europe by simplifying the rules for conducting clinical…


EMA consults on pharmacovigilance changes to medicines information


The European Medicines Agency has launched a public consultation on the changes to the product information…


Human Genome capitulates, accepting raised offer from GlaxoSmithKline


Confirming weekend rumors (The Pharma Letter July 16), UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

FDA approves Truvada, first drug for reducing the risk of sexually acquired HIV infection


Despite protests from consumer groups such as the AIDS Healthcare Foundation (AHF), the US Food and Drug…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

Genmab in collaboration with Janssen for DuoBody platform


Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

BB Biotech rejects privatization proposal by Vontobel Group


Swiss biotechnology investment fund BB Biotech (SIX: BION) has confirmed that Vontobel Group has made…

BB BiotechBiotechnologyEuropeFinancialMergers & AcquisitionsVontobel

Grifols acquires 40% of Spanish biotech firm VCN Bioscience


Spanish health care group Grifols (GRLS: MC), the world's third largest plasma product manufacturer,…

BiotechnologyGrifolsMergers & AcquisitionsOncologyVCN Bioscience

UK's NICE launches new medicines advisory service


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) last Friday launched…

Antibiotics and Infectious diseasesAstellas PharmaBiotechnologyDificlirEuropeGenericsPharmaceuticalRegulation

US drugmakers have almost 200 medicines in development for mental illnesses


Research-based biopharmaceutical companies in the USA are developing 187 innovative medicines to help…

BiotechnologyNeurologicalNorth AmericaPharmaceuticalResearch

Global medicines spending set to rebound, reaching nearly $1.2 trillion by 2016, says IMS


Following several years of slowing growth, the global market for medicines is poised to rebound from…

BiotechnologyGenericsGlobalHealthcareMarkets & MarketingPatentsPharmaceutical

Actelion announces cost saving initiative; Ipsen to hang on to Dreux


Europe largest biotech firm, Actelion (SIX: ATLN) this morning said it has launched a cost saving initiative…


US patients get faster access to more cancer drugs than Europeans, says Tufts


Cancer patients in the USA get faster access to more oncology drugs to treat their disease than patients…

BiotechnologyEuropeHealthcareNorth AmericaOncologyPharmaceuticalPricingRegulation

1890 to 1914 of 2375 results

Back to top